Global Mammalian Cell Fermentation Technology Market Size Study & Forecast, by Type (Hamster Ovary (CHO) Cell Fermentation, Human Embryonic Kidney (HEK) Cell Fermentation, Baby Hamster Kidney (BHK) Cell Fermentation, Murine Myeloma Cell Fermentation, Othe

Global Mammalian Cell Fermentation Technology Market Size Study & Forecast, by Type (Hamster Ovary (CHO) Cell Fermentation, Human Embryonic Kidney (HEK) Cell Fermentation, Baby Hamster Kidney (BHK) Cell Fermentation, Murine Myeloma Cell Fermentation, Others), By Application (Monoclonal Antibodies, Recombinant Proteins, Vaccines, Hormones, Enzymes and Others), By End-use (Biopharmaceutical Companies, CMOs & CDMOs, Academic & Research Institutes) and Regional Analysis, 2023-2030

Global Mammalian Cell Fermentation Technology Market is valued at approximately USD 39.49 billion in 2022 and is anticipated to grow with a growth rate of more than 8.64% over the forecast period 2023-2030. Mammalian cell fermentation, is widely used to create a variety of biosimilars, enzymes, vaccines, and other biologics. It is an essential step in the development of biopharmaceuticals. Mammalian cells are cultured in a bioreactor for fermentation after being produced in vitro from stem cells. The essential byproducts are produced during this process by the cells using a variety of metabolic pathways. The market for Mammalian Cell Fermentation Technology is driven due to factors such as growing prevalence of chronic diseases, growing need for novel and secure therapies and the growing demand for biologics and biosimilars.

Additionally, the rising prevalence of various chronic diseases including cancer is driving the market growth as cancer treatment often involves the use of biologics such as monoclonal antibodies, therapeutic proteins, and vaccines. Mammalian cell fermentation is a crucial method for producing these complex biologics. The demand for biologics rises due to the rising prevalence of cancer, which, in turn, drives the need for mammalian cell fermentation technology. According to the International Agency for Research on Cancer (IARC), it is estimated that there was an increase in the global burden of cancer in 2021 approximately 1.9 million new cases have been recorded, which is projected to account for 27.5 million new cases by 2040. Thus, this factor is propelling the demand for the development of personalized medicines, resulting in market growth, The demand for biologics and biosimilars is driving the market for mammalian cell fermentation technology. These therapies are essential for addressing a number of disorders, such as cancer, autoimmune diseases, and various chronic diseases. In May 2022, Biocon Biologics Ltd. and Viatris Inc. received approval from Health Canada for Abevmy (bevacizumab), a biosimilar to Roche's Avastin (bevacizumab), across four cancer indications. Consequentially, the rising development of biologics and biosimilars is driving market growth. Furthermore, rising technological advancement, as well as the increasing research and development spending by pharmaceutical companies are creating new opportunities to the market. However, the high cost associated with the development of technology is restraining the market growth in the forecast period 2023-2030.

The key regions considered for the Global Mammalian Cell Fermentation Technology Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 with largest market share owing to the region's strong biopharmaceutical industry presence, supportive government regulations, and well-developed healthcare infrastructure. Additionally, the increased demand for biologics and biosimilars as well as the rising prevalence of chronic diseases have contributed to the expansion of the market in the region. Asia Pacific is expected to a fastest growing region during the forecast period, owing to factors such as a big patient population, increasing demand for biologic pharmaceuticals, government initiatives to support biotechnology research and development, and a growth in contract manufacturing organizations (CMOs) in the region, are driving this expansion.

Major market player included in this report are:
Thermo Fisher Scientific, Inc.
Merck KGaA
Danaher Corporation
Lonza Group
Hoffmann-La Roche Ltd
Sartorius AG
AstraZeneca
Bristol-Myers Squibb
Amgen Inc.
Gilead Sciences Inc.

Recent Developments in the Market:
In January 2023, Fosun Pharma and Shanghai Henlius Biotech announced their agreement for the marketing of serplulimab, an anti-PD-1 monoclonal antibody . The agreement is anticipated to broaden Fosun Pharma's biologics portfolio, as well as its manufacturing and development capabilities, in this quickly expanding market.

Global Mammalian Cell Fermentation Technology Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Type, Application, End Use, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Type:
Hamster Ovary (CHO) Cell Fermentation
Human Embryonic Kidney (HEK) Cell Fermentation
Baby Hamster Kidney (BHK) Cell Fermentation
Murine Myeloma Cell Fermentation
Others

By Application:
Monoclonal Antibodies
Recombinant Proteins
Vaccines
Hormones
Enzymes
Others

By End Use:
Biopharmaceutical Companies
CMOs & CDMOs
Academic & Research Institutes

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Thermo Fisher Scientific, Inc.
Merck KGaA
Danaher Corporation
Lonza Group
Hoffmann-La Roche Ltd
Sartorius AG
AstraZeneca
Bristol-Myers Squibb
Amgen Inc.
Gilead Sciences Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.